The flu treatment Relenza looks unlikely to be made available on the National
ÎçÒ¹¸£Àû1000¼¯ºÏ Service in Britain. As New Scientist went to press, the National
Institute for Clinical Excellence was thought to have advised against releasing
the drug, which limits symptoms and hastens recovery. Richard Sykes, chairman of
Glaxo Wellcome, the drug’s maker, is incensed. Yet a company data sheet prepared
in August states that the drug has yet to be shown to work in chronically ill or
immunocompromised patients, who are most at risk from complications of the
flu.
More from New Scientist
Explore the latest news, articles and features
Life
Walking shark found in Papua New Guinea is new to science
News
Mind
Autism may have two distinct subtypes that vary by brain activity
News
Environment
Arctic Ocean reaches tipping point that could be dire for marine life
News
Technology
Technology is changing our perspective on nature – at every scale
Comment
Popular articles
Trending New Scientist articles
1
Sperm have been made magnetic to allow IVF inside the body
2
Has the answer to life's origins been hiding in our cells all along?
3
Fully autonomous drones have killed human soldiers for the first time
4
We may have finally solved cosmology's chicken-or-the-egg problem
5
Global map reveals the vast scale of underground fungal networks
6
The relationship recession is even bigger for Gen Z than we thought
7
Are useful and error-free quantum computers only two years away?
8
Understanding anorexia’s grip on the brain could unlock new therapies
9
The social media ban is an experiment – here’s how it will be studied
10
Technology is changing our perspective on nature – at every scale
